[{"id":"5896371c-1ef5-48dc-96cb-56888e31ddde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150247","created_at":"2025-09-06T13:44:15.174Z","updated_at":"2025-09-06T13:44:15.174Z","phase":"Phase 2","brief_title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150247","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-09-02"},{"id":"883429dd-80b1-4a90-8bbc-e9d0771addf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07135804","created_at":"2025-08-30T14:01:57.585Z","updated_at":"2025-08-30T14:01:57.585Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT07135804","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2025-08-22"},{"id":"bf382896-655a-44da-bab6-a9973e918517","acronym":"","url":"https://clinicaltrials.gov/study/NCT07082179","created_at":"2025-07-26T13:28:21.688Z","updated_at":"2025-07-26T13:28:21.688Z","phase":"Phase 2","brief_title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT07082179","lead_sponsor":"Jiangsu Cancer Institute \u0026 Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-07-24"},{"id":"dd30cd49-1fd8-43e7-b783-449eccebfd62","acronym":"","url":"https://clinicaltrials.gov/study/NCT07070713","created_at":"2025-07-19T14:10:13.961Z","updated_at":"2025-07-19T14:10:13.961Z","phase":"Phase 2","brief_title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","source_id_and_acronym":"NCT07070713","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/30/2025","start_date":" 07/30/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 08/30/2028","study_completion_date":" 08/30/2028","last_update_posted":"2025-07-17"},{"id":"7f4c6188-6f95-4f28-ad01-406cc4472186","acronym":"","url":"https://clinicaltrials.gov/study/NCT07041788","created_at":"2025-06-28T13:37:36.873Z","updated_at":"2025-06-28T13:37:36.873Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","source_id_and_acronym":"NCT07041788","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/10/2025","start_date":" 07/10/2025","primary_txt":" Primary completion: 07/09/2028","primary_completion_date":" 07/09/2028","study_txt":" Completion: 07/09/2030","study_completion_date":" 07/09/2030","last_update_posted":"2025-06-27"},{"id":"ddd7f583-bad9-403a-9835-38c48d3a337c","acronym":"DARTS","url":"https://clinicaltrials.gov/study/NCT07027436","created_at":"2025-06-21T13:17:48.762Z","updated_at":"2025-06-21T13:17:48.762Z","phase":"Phase 3","brief_title":"Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.","source_id_and_acronym":"NCT07027436 - DARTS","lead_sponsor":"Hamilton Health Sciences Corporation","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2025","start_date":" 07/07/2025","primary_txt":" Primary completion: 10/12/2027","primary_completion_date":" 10/12/2027","study_txt":" Completion: 10/10/2028","study_completion_date":" 10/10/2028","last_update_posted":"2025-06-18"},{"id":"09b9b747-24cc-4e7f-8676-9d48960926cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06936748","created_at":"2025-06-21T13:18:57.455Z","updated_at":"2025-06-21T13:18:57.455Z","phase":"Phase 2","brief_title":"SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT06936748","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2025","start_date":" 06/20/2025","primary_txt":" Primary completion: 06/19/2028","primary_completion_date":" 06/19/2028","study_txt":" Completion: 06/19/2029","study_completion_date":" 06/19/2029","last_update_posted":"2025-06-17"},{"id":"435f6562-3a9d-4c61-986e-62e2329bff47","acronym":"CCGLC-017","url":"https://clinicaltrials.gov/study/NCT06954116","created_at":"2025-06-14T13:51:50.396Z","updated_at":"2025-06-14T13:51:50.396Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","source_id_and_acronym":"NCT06954116 - CCGLC-017","lead_sponsor":"Tongji Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2025-06-13"},{"id":"2304e211-cb24-49e4-804c-c1f372c07411","acronym":"ARTEMIDE-HCC01","url":"https://clinicaltrials.gov/study/NCT06921785","created_at":"2025-06-07T14:44:45.235Z","updated_at":"2025-06-07T14:44:45.235Z","phase":"Phase 3","brief_title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT06921785 - ARTEMIDE-HCC01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 1220","initiation":"Initiation: 05/06/2025","start_date":" 05/06/2025","primary_txt":" Primary completion: 03/16/2029","primary_completion_date":" 03/16/2029","study_txt":" Completion: 03/15/2030","study_completion_date":" 03/15/2030","last_update_posted":"2025-05-31"},{"id":"607bb9b9-82b9-4367-a752-246843270b43","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998394","created_at":"2025-06-07T14:48:05.185Z","updated_at":"2025-06-07T14:48:05.185Z","phase":"Phase 2","brief_title":"A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer","source_id_and_acronym":"NCT06998394","lead_sponsor":"Xiangbo Wan","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2025","start_date":" 03/12/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-05-31"},{"id":"f99e9a96-78aa-4611-a09e-0bb82a397f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06967103","created_at":"2025-06-07T15:00:18.246Z","updated_at":"2025-06-07T15:00:18.246Z","phase":"Phase 2","brief_title":"QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06967103","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/30/2029","study_completion_date":" 05/30/2029","last_update_posted":"2025-05-13"},{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"043f12c0-ede0-42eb-a459-538026133635","acronym":"","url":"https://clinicaltrials.gov/study/NCT06946836","created_at":"2025-09-07T01:24:52.108Z","updated_at":"2025-09-07T01:24:52.108Z","phase":"Phase 2","brief_title":"Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study","source_id_and_acronym":"NCT06946836","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/21/2025","start_date":" 04/21/2025","primary_txt":" Primary completion: 05/01/2031","primary_completion_date":" 05/01/2031","study_txt":" Completion: 05/11/2031","study_completion_date":" 05/11/2031","last_update_posted":"2025-04-27"},{"id":"ca3a54db-282a-47be-8c84-13cb7993c8f0","acronym":"GALAXY 3","url":"https://clinicaltrials.gov/study/NCT06926790","created_at":"2025-09-06T17:47:54.931Z","updated_at":"2025-09-06T17:47:54.931Z","phase":"Phase 2","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)","source_id_and_acronym":"NCT06926790 - GALAXY 3","lead_sponsor":"The First Affiliated Hospital of Guangzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 02/17/2025","start_date":" 02/17/2025","primary_txt":" Primary completion: 03/31/2030","primary_completion_date":" 03/31/2030","study_txt":" Completion: 10/31/2030","study_completion_date":" 10/31/2030","last_update_posted":"2025-04-22"},{"id":"0e9bd26b-0254-4ab8-9cad-e1d2a53d9952","acronym":"PRESERVE-003","url":"https://clinicaltrials.gov/study/NCT05671510","created_at":"2023-01-04T14:58:53.390Z","updated_at":"2025-02-25T12:38:29.772Z","phase":"Phase 3","brief_title":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","source_id_and_acronym":"NCT05671510 - PRESERVE-003","lead_sponsor":"OncoC4, Inc.","biomarkers":" LAG3 • CTLA4 • TIGIT","pipe":"","alterations":" ","tags":["LAG3 • CTLA4 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • gotistobart (BNT316)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/28/2023","start_date":" 06/28/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"23898e8b-63ed-4913-ab7c-2d5d7699806b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339571","created_at":"2021-01-18T11:07:01.092Z","updated_at":"2025-02-25T12:26:15.021Z","phase":"Phase 2/3","brief_title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","source_id_and_acronym":"NCT02339571","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 11/23/2015","start_date":" 11/23/2015","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2025-02-24"},{"id":"413aa90a-43b5-4d96-b8cc-5aee512ef199","acronym":"NRG-GY003","url":"https://clinicaltrials.gov/study/NCT02498600","created_at":"2021-01-18T12:02:53.906Z","updated_at":"2025-02-25T12:26:21.840Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02498600 - NRG-GY003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 09/05/2018","primary_completion_date":" 09/05/2018","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"65d9c2cb-0676-43e5-831c-bcc76a373ee1","acronym":"RESOLVE","url":"https://clinicaltrials.gov/study/NCT05154994","created_at":"2021-12-13T14:12:40.514Z","updated_at":"2025-02-25T12:38:04.917Z","phase":"Phase 1","brief_title":"Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma","source_id_and_acronym":"NCT05154994 - RESOLVE","lead_sponsor":"University of Utah","biomarkers":" ARID1A","pipe":"","alterations":" ","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)"],"overall_status":"Suspended","enrollment":" Enrollment 9","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-24"},{"id":"b57cb3c0-4fb2-4fdc-add3-151c7aaf3f51","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT03138161","created_at":"2024-04-18T20:51:31.500Z","updated_at":"2025-02-25T12:26:41.043Z","phase":"Phase 1/2","brief_title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT03138161 - SAINT","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 07/31/2031","study_completion_date":" 07/31/2031","last_update_posted":"2025-02-24"},{"id":"23ac8e6c-a9b5-4a23-995c-206f44787ba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890329","created_at":"2021-01-18T14:11:09.765Z","updated_at":"2025-02-25T13:48:17.623Z","phase":"Phase 1","brief_title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT02890329","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" High ALC","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e High ALC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 08/19/2025","study_completion_date":" 08/19/2025","last_update_posted":"2025-02-21"},{"id":"ed7e0a8d-7121-41ed-982b-5af9f5bc5b3a","acronym":"NRG-GY025","url":"https://clinicaltrials.gov/study/NCT05112601","created_at":"2021-11-09T20:21:18.547Z","updated_at":"2025-02-25T14:16:28.432Z","phase":"Phase 2","brief_title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05112601 - NRG-GY025","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-18"},{"id":"0a44475b-ada6-49fd-a78d-da7cabf4adaa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879162","created_at":"2021-01-18T14:08:03.022Z","updated_at":"2025-02-25T14:14:51.028Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT02879162","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/20/2021","primary_completion_date":" 06/20/2021","study_txt":" Completion: 01/29/2025","study_completion_date":" 01/29/2025","last_update_posted":"2025-02-17"},{"id":"64db0bf5-eaaf-49e9-a532-d5f1928d23e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02537418","created_at":"2021-01-18T12:16:25.434Z","updated_at":"2025-02-25T14:06:52.583Z","phase":"Phase 1","brief_title":"Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens","source_id_and_acronym":"NCT02537418","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1 • PD-1 • CTLA4","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 10/16/2015","start_date":" 10/16/2015","primary_txt":" Primary completion: 07/20/2018","primary_completion_date":" 07/20/2018","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-17"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"}]